Overall Adverse Event Rates Dose Group Any Adverse Event (%) GI Adverse Events (%) Discontinuation Due to AE (%) Placebo 72.1% 32.6% 0% 1 mg 88.6% 48.6% 2.9% 4 mg (escalated) 88.6% 60.0% 5.7% 4 mg (single dose) 90.9% 63.6% 6.1% 8 mg (escalated) 87.5% 57.5% 5.0% 8 mg (single dose) 88.6% 62.9% 5.7% 12 mg (escalated) 97.2% 66.7% 8.3% Source: Jastreboff AM, Kaplan LM, Fras JP, et al
Its deficiency may lead to skin lesions, impaired wound healing, and increased hair loss (243, 251)
Lote: GF-IPA10-B241 Os principais resultados analticos incluem: Teor de ensaio: 10,40 mg Identificao Tempo de reteno: 0,981 Identificao Espectro: 996 Pureza: superior a 99,8 por cento Endotoxinas bacterianas: abaixo de 0,001 EU por mg Contagem total de micrbios aerbicos: no detectada Contagem total de leveduras e bolores: no detetada Uma anlise independente de metais pesados confirmou que no foram detectados nveis de arsnio, cdmio, cobalto, chumbo, nquel, mercrio ou vandio
PubMed laboratory research record [PMID: 40834311] PubMed record related to this compound for laboratory literature review
Glucagon-like peptide 1 (GLP-1)[J]